BioCentury
ARTICLE | Financial News

Cell therapy company Avrobio raises $25M

August 2, 2016 7:00 AM UTC

Avrobio Inc. (Cambridge, Mass.) raised $25 million in a series A round co-led by Atlas Venture, Clarus and SV Life Sciences.

Avrobio has two cell therapy candidates in Phase I testing: AVR-01 to treat acute myelogenous leukemia (AML) and AVR-02 to treat Fabry's disease. AVR-01 contains autologous T cells modified ex vivo to express IL-12, while AVR-02 contains autologous CD34+ hematopoietic stem cells modified to express alpha galactosidase A. Avrobio licensed both candidates from the University Health Network (Toronto, Ontario). ...